|
[Related PubMed/MEDLINE]
Total Number of Papers: 870
|
|
|
| |
|
[Display Entries]
|
|
>> all entries
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
| Page: of |
|
|
|
|
|
Abbreviation Variation
| |
 |
|
EETs (880 times) |
| |
|
|
EETS (2 times) |
| |
|
|
EEts (1 time) |
|
Long Form Variation
| |
|
|
epoxyeicosatrienoic acids (558 times) |
| |
|
|
Epoxyeicosatrienoic acids (211 times) |
| |
|
|
14,15-epoxyeicosatrienoic acids (22 times) |
| |
|
|
epoxygenase-derived epoxyeicosatrienoic acids (13 times) |
| |
|
|
cis-epoxyeicosatrienoic acids (9 times) |
| |
|
|
epoxyeicosatrienoic acid (5 times) |
| |
|
|
eicosanoids epoxyeicosatrienoic acids (3 times) |
| |
|
|
eicosanoids, epoxyeicosatrienoic acids (3 times) |
| |
|
|
epoxyeicosatetraenoic acids (3 times) |
| |
|
|
enzymes to epoxyeicosatrienoic acids (2 times) |
| |
|
|
5,6-epoxyeicosatrienoic acids (2 times) |
| |
|
|
trans-epoxyeicosatrienoic acids (2 times) |
| |
|
|
epoxygenases to epoxyeicosatrienoic acids (2 times) |
| |
|
|
eicosatrienoic acids (2 times) |
| |
|
|
11,12-epoxyeicosatrienoic acids (2 times) |
| |
|
|
epoxy eicosatrienoic acids (2 times) |
| |
|
|
epoxygenases-derived epoxyeicosatrienoic acids (1 time) |
| |
|
|
exogenous epoxyeicosatrienoic acids (1 time) |
| |
|
|
endothelial epoxyeicosatrienoic acids (1 time) |
| |
|
|
Elevated cis-epoxyeicosatrienoic acids (1 time) |
| |
|
|
enzymatic epoxyeicosatrienoic acids (1 time) |
| |
|
|
epoxyeicosatreinoic acids (1 time) |
| |
|
|
Epoxyecosatrienoic acids (1 time) |
| |
|
|
15-epoxyeicosatrienoic acids (1 time) |
| |
|
|
Epoxyeicosatrienoic Acids (1 time) |
| |
|
|
expoxyeicosatrienoic acids (1 time) |
| |
|
|
epoxy-eicosatrienoic acids (1 time) |
| |
|
|
especially epoxyeicosatrienoic acids (1 time) |
| |
|
|
Epoxyeicosatorienoic acids (1 time) |
| |
|
|
Epoxyeicostrienoic acids (1 time) |
| |
|
|
effects: epoxyeicosatrienoic acids (1 time) |
| |
|
|
Eicosatrienoic acids (1 time) |
| |
|
|
epoxyeicosantrienoic acids (1 time) |
| |
|
|
Epoxyeicosatrienoicacids (1 time) |
| |
|
|
elevated epoxyeicosatrienoic acids (1 time) |
| |
|
|
epoxides, epoxyeicosatrienoic acids (1 time) |
| |
|
|
14,15-epoxeicosatrienoic acids (1 time) |
| |
|
|
Epoxieicosatrienoic acids (1 time) |
| |
|
|
enzyme to epoxyeicosatrienoic acids (1 time) |
| |
|
|
endogenous epoxyeicosatrienoic acids (1 time) |
| |
|
|
eight epoxyeicosatrienoic acids (1 time) |
| |
|
|
cis-Epoxyeicosatrienoic acids (1 time) |
| |
|
|
Epoxyeicotrienoic acids (1 time) |
| |
|
|
Epoxyeicosatrienoic acid(s) (1 time) |
| |
|
|
CIS-epoxyeicosatrienoic acids (1 time) |
| |
|
|
8,9-epoxyeicosatrienoic acids (1 time) |
| |
|
|
epidermal epoxyeicosatrienoic acids (1 time) |
| |
|
|
epoxiecocistrienoic acids (1 time) |
| |
|
|
epoxyeicosatrienenoic acids (1 time) |
| |
|
|
epoxyeiscosatrienoic acids (1 time) |
| |
|
|
elevates the epoxyeicosatrienoic acids (1 time) |
| |
|
|
epoxygenase to the epoxyeicosatrienoic acids (1 time) |
| |
|
|
mediators-epoxyeicosatrienoic acids (1 time) |
| |
|
|
epoxygenases to four epoxyeicosatrienoic acids (1 time) |
| |
|
|
epoxygenase to epoxyeicosatrienoic acids (1 time) |
| |
|
|
epoxyeicostrienoic acids (1 time) |
| |
|
|
epoxyeicosatrienoinc acids (1 time) |
| |
|
|
14,15-epoxyeicosatrienoic acid (1 time) |
|
Pair(Abbreviation/Long Form) Variation
| |
|
|
EETs / epoxyeicosatrienoic acids (555 times) |
| |
|
|
EETs / Epoxyeicosatrienoic acids (211 times) |
| |
|
|
EETs / 14,15-epoxyeicosatrienoic acids (22 times) |
| |
|
|
EETs / epoxygenase-derived epoxyeicosatrienoic acids (13 times) |
| |
|
|
EETs / cis-epoxyeicosatrienoic acids (9 times) |
| |
|
|
EETs / epoxyeicosatrienoic acid (5 times) |
| |
|
|
EETs / eicosanoids epoxyeicosatrienoic acids (3 times) |
| |
|
|
EETs / eicosanoids, epoxyeicosatrienoic acids (3 times) |
| |
|
|
EETs / epoxyeicosatetraenoic acids (3 times) |
| |
|
|
EETs / 11,12-epoxyeicosatrienoic acids (2 times) |
| |
|
|
EETs / eicosatrienoic acids (2 times) |
| |
|
|
EETs / trans-epoxyeicosatrienoic acids (2 times) |
| |
|
|
EETs / 5,6-epoxyeicosatrienoic acids (2 times) |
| |
|
|
EETs / epoxy eicosatrienoic acids (2 times) |
| |
|
|
EETS / epoxyeicosatrienoic acids (2 times) |
| |
|
|
EETs / epoxygenases to epoxyeicosatrienoic acids (2 times) |
| |
|
|
EETs / enzymes to epoxyeicosatrienoic acids (2 times) |
| |
|
|
EETs / 14,15-epoxyeicosatrienoic acid (1 time) |
| |
|
|
EETs / 8,9-epoxyeicosatrienoic acids (1 time) |
| |
|
|
EETs / CIS-epoxyeicosatrienoic acids (1 time) |
| |
|
|
EETs / Epoxyeicosatrienoic acid(s) (1 time) |
| |
|
|
EETs / Epoxyeicotrienoic acids (1 time) |
| |
|
|
EETs / cis-Epoxyeicosatrienoic acids (1 time) |
| |
|
|
EETs / eight epoxyeicosatrienoic acids (1 time) |
| |
|
|
EETs / endogenous epoxyeicosatrienoic acids (1 time) |
| |
|
|
EETs / enzyme to epoxyeicosatrienoic acids (1 time) |
| |
|
|
EETs / epidermal epoxyeicosatrienoic acids (1 time) |
| |
|
|
EETs / epoxiecocistrienoic acids (1 time) |
| |
|
|
EETs / epoxyeicosatrienenoic acids (1 time) |
| |
|
|
EETs / epoxyeicosatrienoinc acids (1 time) |
| |
|
|
EETs / epoxyeicostrienoic acids (1 time) |
| |
|
|
EETs / epoxygenase to epoxyeicosatrienoic acids (1 time) |
| |
|
|
EETs / epoxygenase to the epoxyeicosatrienoic acids (1 time) |
| |
|
|
EETs / epoxygenases to four epoxyeicosatrienoic acids (1 time) |
| |
|
|
EETs / mediators-epoxyeicosatrienoic acids (1 time) |
| |
|
|
EEts / epoxyeicosatrienoic acids (1 time) |
| |
|
|
EETs / elevates the epoxyeicosatrienoic acids (1 time) |
| |
|
|
EETs / epoxyeiscosatrienoic acids (1 time) |
| |
|
|
EETs / Epoxieicosatrienoic acids (1 time) |
| |
|
|
EETs / 14,15-epoxeicosatrienoic acids (1 time) |
| |
|
|
EETs / epoxides, epoxyeicosatrienoic acids (1 time) |
| |
|
|
EETs / epoxyeicosatreinoic acids (1 time) |
| |
|
|
EETs / enzymatic epoxyeicosatrienoic acids (1 time) |
| |
|
|
EETs / endothelial epoxyeicosatrienoic acids (1 time) |
| |
|
|
EETs / Epoxyecosatrienoic acids (1 time) |
| |
|
|
EETs / elevated epoxyeicosatrienoic acids (1 time) |
| |
|
|
EETs / Epoxyeicosatrienoicacids (1 time) |
| |
|
|
EETs / epoxyeicosantrienoic acids (1 time) |
| |
|
|
EETs / effects: epoxyeicosatrienoic acids (1 time) |
| |
|
|
EETs / Epoxyeicostrienoic acids (1 time) |
| |
|
|
EETs / Epoxyeicosatorienoic acids (1 time) |
| |
|
|
EETs / especially epoxyeicosatrienoic acids (1 time) |
| |
|
|
EETs / epoxy-eicosatrienoic acids (1 time) |
| |
|
|
EETs / expoxyeicosatrienoic acids (1 time) |
| |
|
|
EETs / epoxygenases-derived epoxyeicosatrienoic acids (1 time) |
| |
|
|
EETs / Eicosatrienoic acids (1 time) |
| |
|
|
EETs / Epoxyeicosatrienoic Acids (1 time) |
| |
|
|
EETs / 15-epoxyeicosatrienoic acids (1 time) |
| |
|
|
EETs / exogenous epoxyeicosatrienoic acids (1 time) |
| |
|
|
EETs / Elevated cis-epoxyeicosatrienoic acids (1 time) |
|
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2020 |
A COX-2/sEH dual inhibitor PTUPB alleviates lipopolysaccharide-induced acute lung injury in mice by inhibiting NLRP3 inflammasome activation. |
ALI, ARA, COX-2, LPS, NLRP3, sEH |
| 2 |
2020 |
A COX-2/sEH dual inhibitor PTUPB ameliorates cecal ligation and puncture-induced sepsis in mice via anti-inflammation and anti-oxidative stress. |
CLP, COX-2, sEH |
| 3 |
2020 |
Apelin inhibits an endothelium-derived hyperpolarizing factor-like pathway in rat cerebral arteries. |
EDHF, NO |
| 4 |
2020 |
Assessment of the Effect of Sorafenib on Omega-6 and Omega-3 Epoxyeicosanoid Formation in Patients with Hepatocellular Carcinoma. |
19,20-EDP, AA, DHA, HCC, PUFAs, sEH |
| 5 |
2020 |
Biosynthesis and immunity of epoxyeicosatrienoic acids in a lepidopteran insect, Spodoptera exigua. |
EPX, RNAi |
| 6 |
2020 |
Combined treatment with epoxyeicosatrienoic acid analog and 20-hydroxyeicosatetraenoic acid antagonist provides substantial hypotensive effect in spontaneously hypertensive rats. |
SHR |
| 7 |
2020 |
Complex interrelationships between nitro-alkene-dependent inhibition of soluble epoxide hydrolase, inflammation and tumor growth. |
DHET, KI, sEH, WT |
| 8 |
2020 |
CYP2J2-produced epoxyeicosatrienoic acids attenuate ischemia/reperfusion-induced acute kidney injury by activating the SIRT1-FoxO3a pathway. |
I/R |
| 9 |
2020 |
Cytochrome 450 metabolites of arachidonic acid (20-HETE, 11,12-EET and 14,15-EET) promote pheochromocytoma cell growth and tumor associated angiogenesis. |
20-HETE, AA, MPC |
| 10 |
2020 |
Cytochrome P450 derived epoxidized fatty acids as a therapeutic tool against neuroinflammatory diseases. |
AD, ARA, EpFAs, PD, sEH |
| 11 |
2020 |
Cytochrome P450 epoxygenase-derived 5,6-epoxyeicosatrienoic acid relaxes pulmonary arteries in normoxia but promotes sustained pulmonary vasoconstriction in hypoxia. |
HPV, IPAs, PASMCs |
| 12 |
2020 |
Eicosanoid blood vessel regulation in physiological and pathological states. |
11,12,15-THETA, 12S-HETE, COX, EDHF, ET-1, LO, PGI2 |
| 13 |
2020 |
Epoxy Fatty Acids: From Salt Regulation to Kidney and Cardiovascular Therapeutics: 2019 Lewis K. Dahl Memorial Lecture. |
--- |
| 14 |
2020 |
Epoxyeicosatrienoic acid prevents maladaptive remodeling in pressure overload by targeting calcineurin/NFAT and Smad-7. |
TAC |
| 15 |
2020 |
Epoxyeicosatrienoic acids inhibit the activation of NLRP3 inflammasome in murine macrophages. |
ALI, ATP, LPS, NLRP3, ROS, sEH |
| 16 |
2020 |
Epoxyeicosatrienoic acids: Emerging therapeutic agents for central post-stroke pain. |
CPSP |
| 17 |
2020 |
Evidence for wall shear stress-dependent t-PA release in human conduit arteries: role of endothelial factors and impact of high blood pressure. |
tPA |
| 18 |
2020 |
Higher Epoxyeicosatrienoic Acids in Cardiomyocytes-Specific CYP2J2 Transgenic Mice Are Associated with Improved Myocardial Remodeling. |
CYP2J2, MI, ROS, TR, WT |
| 19 |
2020 |
Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19? |
ARDS, sEH, SPMs |
| 20 |
2020 |
Inhibition of soluble epoxide hydrolase attenuates renal tubular mitochondrial dysfunction and ER stress by restoring autophagic flux in diabetic nephropathy. |
DN, EpFAs, ER, ESRD, HG, ROS, sEH |
| 21 |
2020 |
Nax-positive glial cells in the organum vasculosum laminae terminalis produce epoxyeicosatrienoic acids to induce water intake in response to increases in [Na+] in body fluids. |
Nax-KO, OVLT, sCVOs, WT |
| 22 |
2020 |
Neuroinflammation is able to downregulate cytochrome P450 epoxygenases 2J3 and 2C11 in the rat brain. |
AA |
| 23 |
2020 |
Peripheral soluble epoxide hydrolase inhibition reduces hypernociception and inflammation in albumin-induced arthritis in temporomandibular joint of rats. |
RA, sEH, TMJ, TPPU |
| 24 |
2020 |
Peroxisome proliferator-activated receptor ɑ (PPARɑ)-cytochrome P450 epoxygenases-soluble epoxide hydrolase axis in ER + PR + HER2- breast cancer. |
PPARalpha, sEH |
| 25 |
2020 |
PET imaging of soluble epoxide hydrolase in non-human primate brain with [18F]FNDP. |
AD, PD, PET, sEH, VCI |
| 26 |
2020 |
Role of epoxyeicosatrienoic acids in the lung. |
--- |
| 27 |
2020 |
Soluble epoxide hydrolase inhibition improves cognitive function and parenchymal artery dilation in a hypertensive model of chronic cerebral hypoperfusion. |
BCAS, CCH, PAs, sEH, SHSRP |
| 28 |
2020 |
The contribution of chymase-dependent formation of ANG II to cardiac dysfunction in metabolic syndrome of young rats: roles of fructose and EETs. |
ACE, AT1R, HFD, MetS, NO, NOX, sEH, TPPU |
| 29 |
2020 |
The interaction Between Arachidonic Acid Metabolism and Homocysteine. |
AA, CVD, Hcy, HETEs, HHcy, PGs, TXA |
| 30 |
2020 |
Time-resolved phosphoproteomic analysis elucidates hepatic 11,12-Epoxyeicosatrienoic acid signaling pathways. |
--- |
| 31 |
2020 |
ZDHXB-101 (3',5-Diallyl-2, 4'-dihydroxy-[1,1'-biphen-yl]-3,5'-dicarbaldehyde) protects against airway remodeling and hyperresponsiveness via inhibiting both the activation of the mitogen-activated protein kinase and the signal transducer and activator of transcription-3 signaling pathways. |
AHR, CYP, IL, JNK, sEH, STAT3 |
| 32 |
2019 |
11,12 and 14,15 epoxyeicosatrienoic acid rescue deteriorated wound healing in ischemia. |
MMP, SD, TIMP |
| 33 |
2019 |
Activation of vitamin D receptor attenuates high glucose-induced cellular injury partially dependent on CYP2J5 in murine renal tubule epithelial cell. |
DN, LDH, STZ, VDR |
| 34 |
2019 |
Alleviation of Mechanical Allodynia by 14,15-Epoxyeicosatrienoic Acid in a Central Poststroke Pain Model: Possible Role of Allopregnanolone and delta-Subunit-Containing Gamma-Aminobutyric Acid A Receptors. |
AP, CPSP, deltaGABAAR |
| 35 |
2019 |
Altered bioavailability of epoxyeicosatrienoic acids is associated with conduit artery endothelial dysfunction in type 2 diabetic patients. |
DHETs, sEH |
| 36 |
2019 |
Altered Renal Vascular Responsiveness to Vasoactive Agents in Rats with Angiotensin II-Dependent Hypertension and Congestive Heart Failure. |
ACF, ACh, Ang II, BK, CHF, NE, RBF, TGRs |
| 37 |
2019 |
Arachidonic Acid Metabolism and Kidney Inflammation. |
19-HETE, AA, COX, CYP450, HETEs, LOX, LTB4, LTs, PG, PGs, TX |
| 38 |
2019 |
Circadian Variation in Vasoconstriction and Vasodilation Mediators and Baroreflex Sensitivity in Hypertensive Rats. |
1K-1C AH, BP, CGRP, CHI, ET-1, HP, SO |
| 39 |
2019 |
CYP2C11 played a significant role in down-regulating rat blood pressure under the challenge of a high-salt diet. |
AA, WT |
| 40 |
2019 |
EETs/PPARs activation together mediates the preventive effect of naringenin in high glucose-induced cardiomyocyte hypertrophy. |
ANF, PPARs |
| 41 |
2019 |
Eicosanoid Profile of Influenza A Virus Infected Pigs. |
HDHAs, HETEs, IAV |
| 42 |
2019 |
Endothelium-dependent adaptation of arterial wall viscosity during blood flow increase is impaired in essential hypertension. |
AWV, HT, NT |
| 43 |
2019 |
Enzymatic Synthesis of Epoxidized Metabolites of Docosahexaenoic, Eicosapentaenoic, and Arachidonic Acids. |
AA, EDPs, EPA, HPLC, MS, NMR, PUFAs, sEH |
| 44 |
2019 |
Epoxyeicosanoids in hypertension. |
sEH |
| 45 |
2019 |
Epoxyeicosatrienoic acid (EET)-stimulated angiogenesis is mediated by epoxy hydroxyeicosatrienoic acids (EHETs) formed from COX-2. |
8,9,11-EHET, COX-2, EET, EHETs, HAECs, PDBu, VEGF |
| 46 |
2019 |
Epoxyeicosatrienoic Acid Analog EET-A Blunts Development of Lupus Nephritis in Mice. |
CXCR, SLE |
| 47 |
2019 |
Epoxyeicosatrienoic acid analog EET-B attenuates post-myocardial infarction remodeling in spontaneously hypertensive rats. |
ECHO, FS, HO-1, MI, SBP, SHR |
| 48 |
2019 |
Epoxyeicosatrienoic Acid-Based Therapy Attenuates the Progression of Postischemic Heart Failure in Normotensive Sprague-Dawley but Not in Hypertensive Ren-2 Transgenic Rats. |
FS, HanSD, HF, LAD, LV, MI, TGR |
| 49 |
2019 |
Epoxyeicosatrienoic acids alleviate methionine-choline-deficient diet-induced non-alcoholic steatohepatitis in mice. |
FFA, MCD, NASH, PPAR-alpha, SREBP-1c |
| 50 |
2019 |
Epoxyeicosatrienoic acids protect pancreatic beta cells against pro-inflammatory cytokine toxicity. |
DM |
| 51 |
2019 |
Expression, purification, and characterisation of human soluble Epoxide Hydrolase (hsEH) and of its functional C-terminal domain. |
hsEH |
| 52 |
2019 |
Increased Soluble Epoxide Hydrolase in Human Gestational Tissues from Pregnancies Complicated by Acute Chorioamnionitis. |
AUDA, CAM, DHETs, LPS, sEH |
| 53 |
2019 |
Inhibition of soluble epoxide hydrolase ameliorates hyperhomocysteinemia-induced hepatic steatosis by enhancing beta-oxidation of fatty acid in mice. |
HHcy, PPAR-alpha, sEH |
| 54 |
2019 |
Inhibition of soluble epoxide hydrolase attenuates a high-fat diet-mediated renal injury by activating PAX2 and AMPK. |
CMA, DHETs, HFD, mRMCs, PA, sEH |
| 55 |
2019 |
Integrated omics-based pathway analyses uncover CYP epoxygenase-associated networks as theranostic targets for metastatic triple negative breast cancer. |
METABRIC, TNBC |
| 56 |
2019 |
Nox4 and soluble epoxide hydrolase synergistically mediate homocysteine-induced inflammation in vascular smooth muscle cells. |
ROS, sEH, VSMC |
| 57 |
2019 |
Obesity in Aging Exacerbates Neuroinflammation, Dysregulating Synaptic Function-Related Genes and Altering Eicosanoid Synthesis in the Mouse Hippocampus: Potential Role in Impaired Synaptic Plasticity and Cognitive Decline. |
LTP |
| 58 |
2019 |
Pharmaceutical Effects of Inhibiting the Soluble Epoxide Hydrolase in Canine Osteoarthritis. |
OA, PGs, PUFAs, sEH, sEHI |
| 59 |
2019 |
Pharmacological Blockade of Soluble Epoxide Hydrolase Attenuates the Progression of Congestive Heart Failure Combined With Chronic Kidney Disease: Insights From Studies With Fawn-Hooded Hypertensive Rats. |
ACF, CHF, CKD, FHH, FHL, sEH |
| 60 |
2019 |
Polymorphisms in vasoactive eicosanoid genes of kidney donors affect biopsy scores and clinical outcomes in renal transplantation. |
20-HETE, eGFR |
| 61 |
2019 |
PPARalpha ligand, AVE8134, and cyclooxygenase inhibitor therapy synergistically suppress lung cancer growth and metastasis. |
11-HETE, AA, COX, ERK, LC, PPARalpha |
| 62 |
2019 |
Preclinical evaluation of EPHX2 inhibition as a novel treatment for inflammatory bowel disease. |
CMap, EPHX2i |
| 63 |
2019 |
Reciprocal actions of constrictor prostanoids and superoxide in chronic hypoxia-induced pulmonary hypertension: roles of EETs. |
ET, HPH, PAAT, RVSP, sEH, sEH-KO, TXA2, VTI, WT |
| 64 |
2019 |
Role of cytochrome epoxygenase (CYP2J2) in the pathophysiology of coronary artery disease in South Indian population. |
CAD, CYP2J2, LDL-C, PCR, TC, TC/HDL |
| 65 |
2019 |
Role of Cytochrome p450 and Soluble Epoxide Hydrolase Enzymes and Their Associated Metabolites in the Pathogenesis of Diabetic Cardiomyopathy. |
CYP2J, DHETs, sEH |
| 66 |
2019 |
Role of epoxy-fatty acids and epoxide hydrolases in the pathology of neuro-inflammation. |
sEH |
| 67 |
2019 |
Role of NF-kappaB in cytochrome P450 epoxygenases down-regulation during an inflammatory process in astrocytes. |
EMSA |
| 68 |
2019 |
sEH Inhibitor TPPU Ameliorates Cecal Ligation and Puncture-Induced Sepsis by Regulating Macrophage Functions. |
CLP, DHETs, sEH |
| 69 |
2019 |
Soluble epoxide hydrolase inhibitor, APAU, protects dopaminergic neurons against rotenone induced neurotoxicity: Implications for Parkinson's disease. |
PD, ROT, sEH |
| 70 |
2019 |
Soluble Epoxide Hydrolase Inhibitor: A Novel Potential Therapeutic or Prophylactic Drug for Psychiatric Disorders. |
EDPs, sEH |
| 71 |
2019 |
TPPU, a sEH Inhibitor, Attenuates Corticosterone-Induced PC12 Cell Injury by Modulation of BDNF-TrkB Pathway. |
CORT, sEH |
| 72 |
2019 |
Vascular repair and anti-inflammatory effects of soluble epoxide hydrolase inhibitor. |
AUDA, HCAECs, IL, IVIG, KD, MMP, sEH, TNF |
| 73 |
2018 |
14,15-epoxyeicosatrienoic acid produced by cytochrome P450s enhances neurite outgrowth of PC12 and rat hippocampal neuronal cells. |
HETEs, TRP |
| 74 |
2018 |
Ablation of soluble epoxide hydrolase reprogram white fat to beige-like fat through an increase in mitochondrial integrity, HO-1-adiponectin in vitro and in vivo. |
HO-1, sEH |
| 75 |
2018 |
Alteration in the availability of epoxyeicosatrienoic acids contributes with NO to the development of endothelial dysfunction in conduit arteries during aging. |
--- |
| 76 |
2018 |
Arachidonic acid in health and disease with focus on hypertension and diabetes mellitus: A review. |
COX, LOX, LXA4 |
| 77 |
2018 |
Combined Inhibition of Soluble Epoxide Hydrolase and Renin-Angiotensin System Exhibits Superior Renoprotection to Renin-Angiotensin System Blockade in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats with Established Chronic Kidney Disease. |
CKD, RAS, sEH, TGR |
| 78 |
2018 |
CYP2J2 Expression in Adult Ventricular Myocytes Protects Against Reactive Oxygen Species Toxicity. |
AA, CYP2J2, ROS |
| 79 |
2018 |
CYP2J2-derived EETs attenuated ethanol-induced myocardial dysfunction through inducing autophagy and reducing apoptosis. |
--- |
| 80 |
2018 |
Cytochrome P450 2J2: Potential Role in Drug Metabolism and Cardiotoxicity. |
AA, CYP2J2 |
| 81 |
2018 |
Deletion of soluble epoxide hydrolase attenuates mice Hyperoxic acute lung injury. |
Keap1, Nrf2, sEH, WT |
| 82 |
2018 |
Discovery of novel drug candidates for inhibition of soluble epoxide hydrolase of arachidonic acid cascade pathway implicated in atherosclerosis. |
AUDA-BE, DHETs, MD, MM/PBSA, sEH |
| 83 |
2018 |
Dronedarone-Induced Cardiac Mitochondrial Dysfunction and Its Mitigation by Epoxyeicosatrienoic Acids. |
AA, ETC, NDBD, NDEA |
| 84 |
2018 |
Effect of angiotensin-converting enzyme blockade, alone or combined with blockade of soluble epoxide hydrolase, on the course of congestive heart failure and occurrence of renal dysfunction in Ren-2 transgenic hypertensive rats with aorto-caval fistula. |
ACF, CHF, RAS, sEH, TGR |
| 85 |
2018 |
Effects of Farnesoid X Receptor Activation on Arachidonic Acid Metabolism, NF-kB Signaling, and Hepatic Inflammation. |
HFD, NAFLD, NF-kB, OCA |
| 86 |
2018 |
Eicosanoids via CYP450 and cardiovascular disease: Hints from genetic and nutrition studies. |
20-HETE, GWAS, SNPs |
| 87 |
2018 |
Endothelium-specific CYP2J2 overexpression attenuates age-related insulin resistance. |
--- |
| 88 |
2018 |
Epoxide hydrolase 1 (EPHX1) hydrolyzes epoxyeicosanoids and impairs cardiac recovery after ischemia. |
DHETs, EPHX1, EPHX2, WT |
| 89 |
2018 |
Expression of cytochrome P450 epoxygenases and soluble epoxide hydrolase is regulated by hypolipidemic drugs in dose-dependent manner. |
PPARalpha, sEH |
| 90 |
2018 |
Expression of soluble epoxide hydrolase in renal tubular epithelial cells regulates macrophage infiltration and polarization in IgA nephropathy. |
sEH |
| 91 |
2018 |
Genetic deletion of 12/15 lipoxygenase promotes effective resolution of inflammation following myocardial infarction. |
HO, LOX, MI, SMA, WT |
| 92 |
2018 |
Heart failure-induced activation of phospholipase iPLA2gamma generates hydroxyeicosatetraenoic acids opening the mitochondrial permeability transition pore. |
AA, cPLA2zeta, HETEs, mPTP |
| 93 |
2018 |
Increased epoxyeicosatrienoic acids may be part of a protective mechanism in human ulcerative colitis, with increased CYP2J2 and reduced soluble epoxide hydrolase expression. |
sEH |
| 94 |
2018 |
Infarct size-limiting effect of epoxyeicosatrienoic acid analog EET-B is mediated by hypoxia-inducible factor-1alpha via downregulation of prolyl hydroxylase 3. |
HIF, PHD3 |
| 95 |
2018 |
Inhibition of Soluble Epoxide Hydrolase 2 Ameliorates Diabetic Keratopathy and Impaired Wound Healing in Mouse Corneas. |
HO-1, sEH, STZ |
| 96 |
2018 |
Inhibition of soluble epoxide hydrolase attenuates eosinophil recruitment and food allergen-induced gastrointestinal inflammation. |
GI, sEH, SPI |
| 97 |
2018 |
Neuroprotective effects of epoxyeicosatrienoic acids. |
sEH |
| 98 |
2018 |
Novel piperidine-derived amide sEH inhibitors as mediators of lipid metabolism with improved stability. |
sEH |
| 99 |
2018 |
Ophiopogonin D Reduces Myocardial Ischemia-Reperfusion Injury via Upregulating CYP2J3/EETs in Rats. |
MI/R, OP-D, SMI |
| 100 |
2018 |
Oxidative Stress and Renal Fibrosis: Recent Insights for the Development of Novel Therapeutic Strategies. |
cGMP-cGK1-PDE, CKD, Cygb, NADPH, NO, Nrf2, PPARgamma, TGF-beta1 |
|
A Search Service for Abbreviation / Long Form
